Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA) > 2 m2

Gynecologic Oncology

Volumn 114, Issue 1, 2009, Pages 53-56

  Schwartz, Joanna ^a   Toste, Beth ^b   Dizon, Don S ^b,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b BROWN UNIVERSITY   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Body surface area; BSA; Endometrial cancer; Obesity; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BODY SURFACE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OBESITY; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY SURFACE AREA; BODY WEIGHT; CARBOPLATIN; FEMALE; FEVER; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; PACLITAXEL; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 67349088339     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.03.010     Document Type: Article

References (20)

1. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of adults. N. Engl. J. Med. 348 (2003) 1625-1638
2. Olsen C.M., Nagle C.M., Whiteman D.C., Purdie D.M., Green A.C., and Webb P.M. Body size and risk of epithelial ovarian and related cancers: a population-based case-control study. Int. J. Cancer 123 (2008) 450-456
3. Leitzman M.F., Koebnick C., Danforth K.N., Brinton L.A., Moore S.C., Hollenbeck A., Schatzkin A., et al. Body mass index and the risk of ovarian cancer. Cancer 115 (2009) 812-822
4. Pavelka J.C., Brown R.S., Karlan B.Y., Cass I., Leuchter R.S., Legasse L.D., et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer 107 (2006) 1520-1524
5. Matthews K.S., Straughn J.M., Kemper M.K., Hoskins K.E., Wang W.W., and Rocconi R.P. The effect of obesity on survival in patients with ovarian cancer. Gynecol. Oncol. 112 (2009) 389-393
6. Greenman C.G., Jagielski C.H., and Griggs J.J. Breast cancer adjuvant chemotherapy dosing in obese patients. Dissemination of information from clinical trials to clinical practice. Cancer 112 10 (2008) 2159-2165
7. Rosner G.L., Hargis J.B., Hollis D.R., Budman D.R., Weiss R.B., Henderson I.C., et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B Study 8541. J. Clin. Oncol. 14 11 (1996) 3000-3008
8. Abdah-Bortnyak R., Tsalic M., and Haim N. Actual body weight for determining doses of chemotherapy in obese patients: evaluation of treatment tolerability. Med. Oncol. 20 4 (2003) 363-368
9. Budman D.R., Berry D.A., Cirrincione C.T., Henderson I.C., Wood W.C., Weiss R.B., et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J. Natl. Cancer Inst. (1998) 1205-1211
10. Lyman G.H. Chemotherapy dose intensity and quality cancer care. Oncology 20 149 (2006) 16-25
11. Wood W.C., Budman D.R., Korzun A.H., Cooper M.R., Younger J., Hart R.D., et al. Dose and dose intensity of adjuvant chemotherapy for stage II node-positive breast carcinoma. New Engl. J. Med. 330 18 (1994) 1253-1259
12. Isonishi S., Yasuda M., Takahashi F., Katsumata N., Kimura E., Aoki D., Jobo T., et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J. Clin. Oncol. 26 (2008) (May 20 suppl; abstr 5506)
13. Griggs J.J., Sorbero M.E.S., and Lyman G.H. Undertreatment of obese women receiving breast cancer chemotherapy. Arch. Int. Med. 165 (2005) 1267-1273
14. Poniewierski M.S., Crawford J., Dale D.C., Culakova E., Kuderer N.M., Wolff D.A., et al. Reduced chemotherapy dose intensity in patients with ovarian cancer: results from a prospective nationwide study. J. Clin. Oncol. 26 (2008) (May 20 suppl; abstr 16508)
15. Modesitt S.C., Tian C., Kryscio R., Thigpen J.T., Randall M.E., Gallion H.H., et al. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gyn. Onc. 105 1 (2007) 59-65
16. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 17 (2003) 3194-3200
17. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., and Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. New Engl. J. Med. 332 (1995) 901-906
18. Mayers C., Panzarella T., and Tannock I.F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91 (2001) 2246-2257
19. Wright J.D., Chunqiao T., Mutch D.G., Herzog T.J., Nagao S., Fujiwara K., et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 109 (2008) 353-358
20. Barrett S.V., Paul J., Hay A., Vasey P.A., Kaye S.B., and Glasspool R.M. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann. Oncol. 19 (2008) 898-902